Pharmacovigilance & Pharmacoepidemiology (Eu2P)
This international Master program offers specializations that meet professional needs in: benefit assessment of medicines, medicine risk identification and quantification, medicine benefit-risk assessment, medicine and public health, medicine risk communication along with an “A la carte” track.
- Cooperation: Collaboration with European universities and experts from regulatory bodies and the pharmaceutical industry. Faculty members* from six academic partners, regulatory partners and industrial partners deliver the Master program curriculum.
- Admission requirements:
- Year 1 requirements: Bachelor degree in Health or Life Sciences.
- Year 2 requirements: Postgraduate degree in Health or Life Sciences along with additional knowledge and experience in statistics, epidemiology and pharmacology.
- Program duration:
- 2 years (120 ECTS).
- Direct access to second year for postgraduate with epidemiology, pharmacology and statistics knowledge.
- Language requirements: Non-native English speakers must provide a certificate proving a minimum of English B2 level according to the “Common European Framework of Reference for Languages” grid (European Union and Council of Europe).
- Level: Joint Master of Science degree. European qualification supported and recognized by the Eu2P regulatory and industrial partners.
- Tuition fees: The tuition fees only change according to full-time professional or student status but do not vary according to location (professionals: 12,000€/year and students: 7,000€/year). No additional costs and no mobility required.
The aim of the Eu2P Master in Pharmacovigilance and Pharmacoepidemiology is to respond to the growing need for well-trained professionals in pharmacovigilance and pharmacoepidemiology highlighted by industry, regulatory and academic bodies. There is a particular need for skilled people, trained in medicine risk-benefit assessment, risk management plan elaboration, risk minimization and risk communication.
Eu2P-trained professionals are qualified for new job profiles such as project managers, pharmacoepidemiological coordinators, risk-benefit analysts and people able to interact with statisticians and clinicians. Eu2P is designed for: non-specialists, graduate and postgraduate students in Health and Life Sciences, healthcare professionals, companies, regulatory agencies and academic institutions.
The Eu2P Master offers six high level curricula track specializations to meet specific professional needs in: benefit assessment of medicine, medicine risk identification and quantification, medicine benefit-risk assessment, medicine and public health, medicine risk communication along with an “A la carte” track.
How to apply?
Applicants must complete the on-line application procedure on the:
Master applications may be submitted from February to June. Selection is made during the first two weeks of July.
- France: University of Bordeaux (academic coordinator)
- Italy: Università della Campania Luigi Vanvitelli, Napoli
- The Netherlands: Erasmus Universitair Medisch Centrum Rotterdam / Universiteit Utrecht
- Spain: Universitat Autònoma de Barcelona
- U.K.: University of Hertfordshire
- European Medicines Agency
- Agence Nationale de Sécurité du Médicament et des Produits de Santé
- Belgium: Amgen / Janssen Pharmaceutica / UCB Pharma
- Denmark: Novo Nordisk / Lundbeck
- Finland: Orion Corporation
- France: Iqvia / Sanofi
- Germany: Bayer Pharma / Boehringer Ingelheim International
- Spain: Almirall
- Sweden: AstraZeneca
- Switzerland: Hoffmann-La Roche AG / Novartis Pharma
- U.K.: Eli Lilly / GlaxoSmithKline Research and Development / Shire